CME

CME Group Inc. Financial Services - Exchanges Investor Relations →

NO
14.8% ABOVE
↑ Moving away Was 12.8% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $213.41
14-Week RSI 36
Rel. Volume (14w) This week's trading vs. the 14-week average 1.0x
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 0.93

CME Group Inc. (CME) closed at $245.05 as of 2026-07-17, trading 14.8% above its 200-week moving average of $213.41. The stock moved further from the line this week, up from 12.8% last week. The 14-week RSI sits at 36, indicating neutral momentum.

Trading volume is running at 1.0x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.93 ratio) is neutral — neither side is clearly dominating.

Over the past 1184 weeks of data, CME has crossed below its 200-week moving average 9 times. On average, these episodes lasted 26 weeks. Historically, investors who bought CME at the start of these episodes saw an average one-year return of +28.7%.

With a market cap of $88.5 billion, CME is a large-cap stock. The company generates a free cash flow yield of 3.4%. Return on equity stands at 15.9%, a solid level. The stock trades at 3.3x book value.

CME passes our Buffett quality screen: high return on equity, low debt, and positive free cash flow.

Over the past 22.8 years, a hypothetical investment of $100 in CME would have grown to $3728, compared to $1060 for the S&P 500. That represents an annualized return of 17.2% vs 10.9% for the index — confirming CME as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.

Free cash flow has been growing at a 12.2% compound annual rate, with 4 consecutive years of positive cash generation.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Growth of $100: CME vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After CME Crosses Below the Line?

Across 9 historical episodes, buying CME when it crossed below its 200-week moving average produced an average return of +26.0% after 12 months (median +19.0%), compared to +21.7% for the S&P 500 over the same periods. 89% of those episodes were profitable after one year. After 24 months, the average return was +46.6% vs +37.2% for the index.

Each line shows $100 invested at the moment CME crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Bean Score Experimental

The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices CME would reach each dislocation threshold.

Current Bean Score +1.85σ
Current FCF Yield 5.06%
Baseline Yield 3.95%
Historical σ 0.58pp

Dislocation Price Levels

Prices where CME's Bean Score would hit each σ threshold. Valid until next earnings report: 2026-07-22.

LevelσPriceSignal
Deep Value+2σ$232.71Unusually cheap — potential buy zone
Value+1σ$262.49Cheap vs. own history
Fair Value+0σ$301.02Historical mean behavior
Expensive-1σ$352.79Expensive vs. own history
Deep Expensive-2σ$426.08Unusually expensive — potential trim zone

Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end

Data depth: 2 quarterly baselines, 26 price observations — Limited history (4+ quarters preferred for reliability)

Signal Accuracy Collecting Data

The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"

12 / 13 weeks minimum

Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.

Dislocation Scores Experimental

Each score measures deviation from CME's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.

Yield Dislocation +0.06σ Dividend yield vs own 10-yr norm
Drawdown Score +0.45σ Distance from line vs own history
Sector-Relative N/A Vs sector median this week
Buyback Acceleration -0.2pp YoY share change vs own 3-yr pace (− = accelerating)
Insider Intensity 9th TTM buys / market cap, percentile of buyers
FCF Yield vs History -1.5pp Vs own recent annual mean
Earnings Quality Stable Accrual gap trend (+1.2pp of revenue)

Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.

Advertisement

Historical Touches

CME has crossed below its 200-week MA 9 times with an average 1-year return of +28.7% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Jun 2008Feb 201219260.3%-11.1%+536.3%
Apr 2012Jun 201264.3%+19.9%+735.0%
Jul 2012Aug 201253.4%+55.6%+743.4%
Dec 2012Dec 201233.8%+63.2%+732.5%
Oct 2020Nov 202025.9%+51.0%+106.1%
Sep 2022Feb 2023209.3%+17.1%+60.8%
Mar 2023Mar 202314.2%+27.7%+60.5%
May 2023May 202323.5%+22.8%+54.2%
Jun 2023Jun 202310.2%+12.1%+53.4%
Average26+28.7%

Frequently Asked Questions

Is CME below its 200-week moving average?

No. CME Group Inc. (CME) is currently 14.8% above its 200-week moving average of $213.41. It would need to fall to $213.41 to cross below the line.

What is CME's 200-week moving average price?

CME Group Inc.'s 200-week moving average is $213.41 as of 2026-07-17. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

What happens when CME drops below its 200-week moving average?

CME has crossed below its 200-week moving average 9 times in our data. On average, buying at that moment produced a one-year return of +28.7%. These dips have historically been decent entry points. These episodes lasted 26 weeks on average.

Is CME a good value right now?

Here's what our data says about CME as of 2026-07-17: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 36. Free cash flow yield is 3.4%. Return on equity is 15.9%. Price-to-book is 3.3x. This is not a buy or sell recommendation — always do your own research.

How does CME compare to the S&P 500?

Over the past 22.8 years, $100 invested in CME would have grown to $3728, compared to $1060 for the S&P 500. That's 17.2% annualized vs 10.9% for the index. CME has outperformed the broader market over this period.

Does CME pay a dividend?

Yes. CME Group Inc. currently pays a dividend yield of 211.00%.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-07-17